Patents by Inventor Kenneth James Henry, Jr.

Kenneth James Henry, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTK inhibitor compounds
    Patent number: 11542249
    Abstract: The invention provides BTK Inhibitor compounds of the formula pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 3, 2023
    Assignee: Eli Lilly and Company
    Inventors: Kenneth James Henry, Jr., Albert Khilevich, Steven Lee Kuklish, Katherine Marie Partridge, Steven James Quimby
  • BTK INHIBITOR COMPOUNDS
    Publication number: 20200290997
    Abstract: The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
    Type: Application
    Filed: October 30, 2018
    Publication date: September 17, 2020
    Inventors: Kenneth James Henry, Jr., Albert Khilevich, Steven Lee Kuklish, Katherine Marie Partridge, Steven James Quimby
  • AKT inhibitors
    Patent number: 8436002
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: May 7, 2013
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, Jr., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • AKT INHIBITORS
    Publication number: 20120149684
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Application
    Filed: October 20, 2010
    Publication date: June 14, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, JR., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors
    Patent number: 7745438
    Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Howard Barff Broughton, Robert Dean Dally, Timothy Barrett Durham, Maria Rosario Gonzalez-Garcia, Patric James Hahn, Kenneth James Henry, Jr., Todd Jonathan Kohn, James Ray McCarthy, Timothy Alan Shepherd, Jon Andre Erickson, Ana Belen Bueno Melendo
  • 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
    Patent number: 7449477
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
  • Inhibitors of Akt (protein kinase B)
    Patent number: 7414063
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza